CRDF Q3 2024 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$165,000+17.0% YoY

Gross Profit

-$9M-5742.4% margin

Operating Income

-$13M-7637.0% margin

Net Income

-$12M-7184.8% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+1.2%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$63M

Total Liabilities

$14M

Stockholders' Equity

$49M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$165,000	$141,000	+17.0%
Gross Profit	-$9M	$34,000	-27967.6%
Operating Income	-$13M	-$11M	-16.5%
Net Income	-$12M	-$10M	-21.8%